Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

GUILFORD, Conn.--(BUSINESS WIRE)--March 6, 2023--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place, Boston, MA on March 6-8, 2023.

Quantum-Si to Participate in the 43rd Annual Cowen Health Care Conference

Quantum-Si to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.

Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with Biovista to provide customers greater proteomic insights beyond their protein sequence output. Biovista leverages AI in multiple formats to analyze massive data repositories and visualize non-obvious networks and associations between proteins, diseases, and drug mechanisms-of-action. The partnership enhances Quantium-Si's offering by making proteomic-to-drug workflows more efficient for researchers.

Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform Output

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets. This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.

Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing

Quantum-Si's technology has potential in drug discovery and biomarker test development. The company's Platinum sequencing platform is set to launch.

Revolutionizing Protein Sequencing: Quantum-Si's Single-Molecule Technology

GUILFORD, Conn.--( BUSINESS WIRE )--Dec. 22, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place at the Westin St. Francis, San Francisco, CA on January 9-12, 2023.

Quantum-Si to Participate in the 41st Annual J.P. Morgan Healthcare Conference

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world's first next-generation single-molecule protein sequencing platform. Platinum will be offered at an unprecedented low price-point of $70,000, while its small 19.5 inch by 8.5 inch footprint benchtop design is poised to greatly improve access to high-resolution protein sequencing data, ultimately accelerating breakthroughs across scientific disciplines—from drug discovery to biotech—and helping people live healthier and longer lives.

Quantum-Si Announces Commercial Availability of PlatinumTM, the World's First Next-Generation Single-Molecule Protein Sequencing Platform

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere. Dan Hanson, Director of Product, and Dr. Brian Reed, Head of Research, will represent Quantum-Si and support HUPO's mission to advance proteomics technologies, techniques and training to better understand human disease.

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Cyxtera Technologies

It's a good time to start looking for millionaire-maker penny stocks. Inflationary pressures are starting to come down, and the market has started to creep higher.

3 Millionaire-Maker Penny Stocks You Will Regret Not Buying This Year

Quantum-Si incorporated (NASDAQ:QSI ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Juan Avendano - Head, Investor Relations Dr. Jonathan Rothberg - Founder and Chairman Jeff Hawkins - Chief Executive Officer Patrick Schneider - President and COO Claudia Drayton - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Brandon Carney - B. Riley Operator Ladies and gentlemen, thank you for standing by.

Quantum-Si incorporated (QSI) Q3 2022 Earnings Call Transcript

Quantum-Si Reports Third Quarter 2022 Financial Results

Quantum-Si to Participate in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Quantum-Si to Report Third Quarter 2022 Financial Results on November 7, 2022

Quantum-Si's Next-Generation Single-Molecule Protein Sequencing Technology Published in Science, Signaling New Era of Life Science and Biomedical Research

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Appoints Jeff Hawkins as Chief Executive Officer

Quantum-Si Appoints Jeff Hawkins as Chief Executive Officer

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Quantum-Si to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Quantum-Si incorporated (NASDAQ:QSI ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Juan Avendano - Head, Investor Relations Jonathan Rothberg - Interim Chief Executive Officer Patrick Schneider - President and Chief Operating Officer Claudia Drayton - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Operator Ladies and gentlemen, thank you for standing by and welcome to the Quantum-Si Second Quarter 2022 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Quantum-Si incorporated (QSI) CEO Jonathan Rothberg on Q2 2022 Results - Earnings Call Transcript

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Second Quarter 2022 Financial Results

Quantum-Si Reports Second Quarter 2022 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Second Quarter 2022 Financial Results on August 8, 2022

Quantum-Si to Report Second Quarter 2022 Financial Results on August 8, 2022

GUILFORD, Conn.--(BUSINESS WIRE)--June 22, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, is set to join the broad-market Russell 2000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted by FTSE Russell on June 3, 2022. Annual Russell indexes reconstituti

Quantum-Si Set to Join the Russell 2000® Index

GUILFORD, Conn.--(BUSINESS WIRE)--June 16, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced the appointment of Vikram Bajaj, Ph.D., co-founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences), to its Board of Directors. Dr. Bajaj is a managing director at Foresite Capital, evaluating and pursuing investments at the intersection of technology

Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors

GUILFORD, Conn.--(BUSINESS WIRE)--Jun. 1, 2022 -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, announced that Brian Reed, Ph.D., Head of Research at Quantum-Si, presented an update on the Company's technology advancements at the Next-Generation Protein Analysis and Detection Conference, a VIB Tools & Technologies conference, in Ghent, Belgium. The presentation is available on the Inv

Quantum-Si Highlights Technology Advancements at the VIB Next-Generation Protein Analysis and Detection Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Present at the 2022 Jefferies Healthcare Conference

News for Quantum-Si Stock (QSI)